How to predict and prevent the immunogenicity of therapeutic proteins.
about
Therapeutic antibodies, vaccines and antibodyomesProtein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profilesBiophysical evaluation of aminoclay as an effective protectant for protein stabilization during freeze-drying and storageElimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins.Coral snake antivenom produced in chickens (Gallus domesticus).Engineered protein A ligands, derived from a histidine-scanning library, facilitate the affinity purification of IgG under mild acidic conditions.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsStructural basis of IL-23 antagonism by an Alphabody protein scaffoldTherapeutic antibodies against cancer.Effects of disulfide bond formation and protein helicity on the aggregation of activating transcription factor 5Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure.Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.Silk constructs for delivery of musculoskeletal therapeutics.Engineering the variable region of therapeutic IgG antibodies.Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Protein particulate detection issues in biotherapeutics development--current status.Molecular engineering of antibodies for therapeutic and diagnostic purposes.The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics.Novel drug discovery strategies for gout.Preclinical models used for immunogenicity prediction of therapeutic proteins.The immunogenicity of polyethylene glycol: facts and fiction.Assessment of the metabolism of therapeutic proteins and antibodies.Serelaxin in clinical development: past, present and future.Protein release from biodegradable polyHPMA-lysozyme conjugates resulting in bioactivity enhancement.Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon betaHost cell proteins in biotechnology-derived products: A risk assessment framework.Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory.Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents.A novel rapid and continuous procedure for large-scale purification of magnetosomes from Magnetospirillum gryphiswaldense.Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins
P2860
Q24599662-1CFDABD4-4AD3-4DFB-8BC4-D24375D6136DQ26998787-B63A234D-96E3-40C2-A8C2-334E4AA6B389Q30396724-01280263-D24C-4747-B753-7E1A82FFBA64Q33652098-C7F02365-A191-4476-9C81-FB9ED45A814DQ33784812-61742B0C-3574-47EB-8F83-57AACAF61DCAQ33859599-D88A4838-7BDC-4A35-8914-673FC6D50584Q33936317-6A6B683E-61E9-4160-88AE-4995384471DEQ34110768-77E37FEB-2CF8-4D63-83A4-67F60C3F65D0Q34445379-942F4B90-CEA7-45F4-9D5A-63E2AA4215F1Q35908498-63E870A9-0527-49BA-B7F7-492ADF900DE7Q36149364-A1F4247F-A7DF-44B6-80A4-698C311C554FQ36331505-1CDE734B-2C65-4E9A-A68C-EA14126E2F97Q36359728-7AE98983-2F53-491B-98F0-0124E1143C42Q36411853-7F2D2E98-2CFD-42F2-BC0A-413C41E74DC5Q36650003-B5093698-443F-432C-AF08-C53CE6000C07Q37035579-165B62C7-E889-4EDE-BB7D-5B65057AC2C4Q37853324-752EF874-76EA-4976-82CF-12B7E0C93A41Q37999380-AEE48BAF-15C5-4047-A1D4-AF9658D77977Q38008257-FEDDD08D-FB24-4A6C-B985-96E561A9CA67Q38017581-8005981B-777A-416D-BCB5-5432F2507513Q38058750-10DD4824-9CD7-4EE4-B997-321C023D6FF3Q38066561-3EAC235C-2E12-448E-B74D-785588FC4889Q38104674-DA40F5DB-ABFD-497E-8870-554AA6A516F8Q38106847-BD03D6BE-A729-48D7-87CB-DB7150E8F046Q38217623-1AC37AB4-4635-4D2F-AFD5-EE481FE016C7Q38778886-CBF1D78C-8B10-4210-AB84-09E4410DA9CBQ39574234-7210FDC1-2DCF-472B-B2AF-693A7902753AQ41620233-CE693F8B-C735-40AF-85C7-E3DFCD966685Q43618464-BB918AFC-84AB-4C95-AC9D-1D8C0EB6720CQ44805804-D57B06E0-40A3-41D6-AC85-15545A29D271Q45717861-E861DE95-63CC-4FF0-8D99-8C6AF1B3E887Q52608509-C7FCD937-2006-4FB1-8BED-E1CE6E90DE4EQ58869607-150E0472-805A-4B92-A586-84A1EEF7B0EF
P2860
How to predict and prevent the immunogenicity of therapeutic proteins.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How to predict and prevent the immunogenicity of therapeutic proteins.
@en
How to predict and prevent the immunogenicity of therapeutic proteins.
@nl
type
label
How to predict and prevent the immunogenicity of therapeutic proteins.
@en
How to predict and prevent the immunogenicity of therapeutic proteins.
@nl
prefLabel
How to predict and prevent the immunogenicity of therapeutic proteins.
@en
How to predict and prevent the immunogenicity of therapeutic proteins.
@nl
P1476
How to predict and prevent the immunogenicity of therapeutic proteins.
@en
P2093
Huub Schellekens
P304
P356
10.1016/S1387-2656(08)00007-0
P577
2008-01-01T00:00:00Z